An emerging place for lung cancer genomics in 2013
- PMID:24163742
- PMCID: PMC3804884
- DOI: 10.3978/j.issn.2072-1439.2013.10.06
An emerging place for lung cancer genomics in 2013
Abstract
Lung cancer is a disease with a dismal prognosis and is the biggest cause of cancer deaths in many countries. Nonetheless, rapid technological developments in genome science promise more effective prevention and treatment strategies. Since the Human Genome Project, scientific advances have revolutionized the diagnosis and treatment of human cancers, including thoracic cancers. The latest, massively parallel, next generation sequencing (NGS) technologies offer much greater sequencing capacity than traditional, capillary-based Sanger sequencing. These modern but costly technologies have been applied to whole genome-, and whole exome sequencing (WGS and WES) for the discovery of mutations and polymorphisms, transcriptome sequencing for quantification of gene expression, small ribonucleic acid (RNA) sequencing for microRNA profiling, large scale analysis of deoxyribonucleic acid (DNA) methylation and chromatin immunoprecipitation mapping of DNA-protein interaction. With the rise of personalized cancer care, based on the premise of precision medicine, sequencing technologies are constantly changing. To date, the genomic landscape of lung cancer has been captured in several WGS projects. Such work has not only contributed to our understanding of cancer biology, but has also provided impetus for technical advances that may improve our ability to accurately capture the cancer genome. Issues such as short read lengths contribute to sequenced libraries that contain challenging gaps in the aligned genome. Emerging platforms promise longer reads as well as the ability to capture a range of epigenomic signals. In addition, ongoing optimization of bioinformatics strategies for data analysis and interpretation are critical, especially for the differentiation between driver and passenger mutations. Moreover, broader deployment of these and future generations of platforms, coupled with an increasing bioinformatics workforce with access to highly sophisticated technologies, could see many of these discoveries translated to the clinic at a rapid pace. We look forward to these advances making a difference for the many patients we treat in the Asia-Pacific region and around the world.
Keywords: High-throughput nucleotide sequencing; genomics; lung neoplasms; non-small cell lung carcinoma (NSCLC); small cell lung carcinoma (SCLC).
Similar articles
- Whole genome sequencing for lung cancer.Daniels M, Goh F, Wright CM, Sriram KB, Relan V, Clarke BE, Duhig EE, Bowman RV, Yang IA, Fong KM.Daniels M, et al.J Thorac Dis. 2012 Apr 1;4(2):155-63. doi: 10.3978/j.issn.2072-1439.2012.02.01.J Thorac Dis. 2012.PMID:22833821Free PMC article.
- Next-Generation Sequencing: The Translational Medicine Approach from "Bench to Bedside to Population".Beigh MM.Beigh MM.Medicines (Basel). 2016 Jun 2;3(2):14. doi: 10.3390/medicines3020014.Medicines (Basel). 2016.PMID:28930123Free PMC article.Review.
- Next-generation sequencing in the clinic: promises and challenges.Xuan J, Yu Y, Qing T, Guo L, Shi L.Xuan J, et al.Cancer Lett. 2013 Nov 1;340(2):284-95. doi: 10.1016/j.canlet.2012.11.025. Epub 2012 Nov 19.Cancer Lett. 2013.PMID:23174106Free PMC article.Review.
- Next-Generation Sequencing and Emerging Technologies.Kumar KR, Cowley MJ, Davis RL.Kumar KR, et al.Semin Thromb Hemost. 2019 Oct;45(7):661-673. doi: 10.1055/s-0039-1688446. Epub 2019 May 16.Semin Thromb Hemost. 2019.PMID:31096307Review.
- [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].Pécuchet N, Legras A, Laurent-Puig P, Blons H.Pécuchet N, et al.Ann Pathol. 2016 Jan;36(1):80-93. doi: 10.1016/j.annpat.2015.11.012. Epub 2016 Jan 20.Ann Pathol. 2016.PMID:26803564French.
Cited by
- Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancer.Mahajan A, B G, Wadhwa S, Agarwal U, Baid U, Talbar S, Janu AK, Patil V, Noronha V, Mummudi N, Tibdewal A, Agarwal JP, Yadav S, Kumar Kaushal R, Puranik A, Purandare N, Prabhash K.Mahajan A, et al.Explor Target Antitumor Ther. 2023;4(4):657-668. doi: 10.37349/etat.2023.00158. Epub 2023 Aug 30.Explor Target Antitumor Ther. 2023.PMID:37745691Free PMC article.
- MiR-133a is downregulated in non-small cell lung cancer: a study of clinical significance.Lan D, Zhang X, He R, Tang R, Li P, He Q, Chen G.Lan D, et al.Eur J Med Res. 2015 Apr 23;20(1):50. doi: 10.1186/s40001-015-0139-z.Eur J Med Res. 2015.PMID:25903369Free PMC article.
- Comparison of clinical characteristics and overall survival between spirometrically diagnosed chronic obstructive pulmonary disease (COPD) and non-COPD never-smoking stage I-IV non-small cell lung cancer patients.Lim JU, Yeo CD, Rhee CK, Kang HS, Park CK, Kim JS, Kim JW, Kim SJ, Yoon HK, Lee SH.Lim JU, et al.Int J Chron Obstruct Pulmon Dis. 2019 May 1;14:929-938. doi: 10.2147/COPD.S190244. eCollection 2019.Int J Chron Obstruct Pulmon Dis. 2019.PMID:31118602Free PMC article.
- Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives.Cheng X, Chen H.Cheng X, et al.Onco Targets Ther. 2014 Sep 23;7:1689-704. doi: 10.2147/OTT.S66502. eCollection 2014.Onco Targets Ther. 2014.PMID:25285017Free PMC article.Review.
- US lung cancer trends by histologic type.Lewis DR, Check DP, Caporaso NE, Travis WD, Devesa SS.Lewis DR, et al.Cancer. 2014 Sep 15;120(18):2883-92. doi: 10.1002/cncr.28749. Epub 2014 Aug 11.Cancer. 2014.PMID:25113306Free PMC article.
References
- Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide Lyon, France: International Agency for Research on Cancer, 2010. Available online:http://globocan.iarc.fr
- Lung cancer: a global scourge. Lancet 2013;382:659. - PubMed
- Cancer survival and prevalence in Australia: Cancers diagnosed from 1982-2004. Canberra: Australian Institute of Health and Welfare; Cancer Australia; The Australasian Association of Cancer Registries, July 2008. Report No.: Contract No.: Sept 12.
- Parikh P, Puri T.Personalized medicine: Lung Cancer leads the way. Indian J Cancer 2013;50:77-9 - PubMed
- Sanger F, Coulson AR. A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol 1975;94:441-8 - PubMed
Publication types
LinkOut - more resources
Full Text Sources